Clinical outcomes in octogenarians treated with docetaxel as first-line chemotherapy for castration-resistant prostate cancer

Future Oncology

Volumn 12, Issue 4, 2016, Pages 493-502

  Veccia, Antonello ^a   Caffo, Orazio ^a   De Giorgi, Ugo ^b   Di Lorenzo, Giuseppe ^c   Ortega, Cinzia ^d   Scognamiglio, Florinda ^e   Aieta, Michele ^f   Facchini, Gaetano ^g   Mansueto, Giovanni ^h   Mattioli, Rodolfo ⁱ   Procopio, Giuseppe ^j   Zagonel, Vittorina ^k   D'Angelo, Alessandro ^l   Spizzo, Gilbert ^m   Bortolus, Roberto ⁿ   Donini, Maddalena ^o   Lo Re, Giovanni ^p   Massari, Francesco ^q   Vicario, Giovanni ^r   Zucali, Paolo A ^s   Alesini, Daniele ^t   Bonetti, Andrea ^u   Mucciarini, Claudia ^v   Nicodemo, Maurizio ^w   Berruti, Alfredo ^x   Fratino, Lucia ⁿ   Lodde, Michele ^y   Messina, Caterina ^z   Perin, Alessandra ^aa   Santini, Daniele ^ab   Sava, Teodoro ^ac   Tucci, Marcello ^ad   Basso, Umberto ^k   Maines, Francesca ^a   Burgio, Luca S ^b   Galligioni, Enzo ^a   more..

^a SANTA CHIARA HOSPITAL   (Italy)

^b DEPARTMENT OF MEDICAL ONCOLOGY   (Italy)

^c FEDERICO II UNIVERSITY HOSPITAL   (Italy)

^d CANDIOLO CANCER INSTITUTE   (Italy)

^e CARDARELLI HOSPITAL   (Italy)

^f REFERRAL CANCER CENTER OF BASILICATA   (Italy)

^g NATIONAL CANCER INSTITUTE   (Italy)

^h Section of Nephrology Umberto I   (Italy)

ⁱ S CROCE E CARLE HOSPITAL   (Italy)

^j NATIONAL CANCER INSTITUTE   (Italy)

^k VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

^l San Vincenzo Hospital   (Italy)

^m Medical Oncology Department   (Italy)

ⁿ CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^o CREMONA HOSPITAL   (Italy)

^p S MARIA DEGLI ANGELI HOSPITAL   (Italy)

^q UNIVERSITY HOSPITAL OF VERONA   (Italy)

^r Department of General Surgery   (Italy)

^s HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^t SAPIENZA UNIVERSITY OF ROME   (Italy)

^u Mater Salutis Hospital   (Italy)

^v Ramazzini Hospital   (Italy)

^w SACRO CUORE DON CALABRIA HOSPITAL   (Italy)

^x SPEDALI CIVILI   (Italy)

^y GENERAL HOSPITAL   (Italy)

^z PAPA GIOVANNI XXIII HOSPITAL   (Italy)

^aa General Hospital   (Italy)

^ab UNIVERSITY CAMPUS BIO MEDICO   (Italy)

^ac University and General Hospital   (Italy)

^ad UNIVERSITY OF TURIN   (Italy)

more..

Author keywords

castration resistant prostate cancer; docetaxel; elderly; geriatric assessment

Indexed keywords

ABIRATERONE ACETATE; CABAZITAXEL; DOCETAXEL; ENZALUTAMIDE; ANTINEOPLASTIC AGENT; TAXOID;

AGED; ANEMIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; DIARRHEA; DRUG EFFICACY; DRUG TOLERABILITY; EDEMA; FATIGUE; FEBRILE NEUTROPENIA; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAIL DISEASE; NAUSEA; NEUROPATHY; NEUTROPENIA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; STOMATITIS; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT OUTCOME; VOMITING; WEIGHT REDUCTION; CLINICAL TRIAL; MORTALITY; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; RETREATMENT; VERY ELDERLY;

AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; HUMANS; MALE; PROPORTIONAL HAZARDS MODELS; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; RETREATMENT; RETROSPECTIVE STUDIES; TAXOIDS; TREATMENT OUTCOME;

EID: 84957695804     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.15.302     Document Type: Article

References (29)

1. Siegel R, Ma J, Miller K, Jemal A. Cancer statistics, 2015. CA Cancer J. Clin. 65, 5-29 (2015).
2. Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur. J. Cancer 49, 1374-1403 (2013).
3. Fung C, Dale W, Mohile SG. Prostate cancer in the elderly patient. J. Clin. Oncol. 32, 2523-2530. (2014).
4. Aapro MS. Management of advanced prostate cancer in senior adults: the new landscape. Oncologist 17(Suppl. 1), 16-22 (2012).
5. Petrylak DP, Tangen CM, Hussain MH et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N. Engl. J. Med. 351, 1513-1520 (2004).
6. Tannock IF, de Wit R, Berry WR et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N. Engl. J. Med. 351, 1502-1512 (2004).
7. Sternberg CN, de Bono JS, Chi KN et al. Improved outcomes in elderly patients with metastatic castration-resistant prostate cancer treated with the androgen receptor inhibitor enzalutamide: results from the Phase III AFFIRM trial. Ann Oncol. 25, 429-434 (2014).
8. Mulders PF, Molina A, Marberger M et al. Efficacy and safety of abiraterone acetate in an elderly patient subgroup (aged 75 and older) with metastatic castration-resistant prostate cancer after docetaxel-based chemotherapy. Eur. Urol. 65, 875-883 (2014).
9. Horgan AM, Seruga B, Pond GR et al. Tolerability and efficacy of docetaxel in older men with metastatic castrate-resistant prostate cancer (mCRPC) in the TAX 327 trial. J. Geriatr. Oncol. 5, 119-126 (2014).
10. Droz JP, Aapro M, Balducci L et al. Management of prostate cancer in older patients: updated recommendations of a working group of the International Society of Geriatric Oncology. Lancet Oncol. 15, e404-e414 (2014).
11. Piccirillo JF, Vlahiotis A, Barrett LB et al. The changing prevalence of comorbidity across the age spectrum. Crit. Rev. Oncol. Hematol. 67, 124-132 (2008).
12. Beer TM, Berry W, Wersinger EM, Bland LB. Weekly docetaxel in elderly patients with prostate cancer: efficacy and toxicity in patients at least 70 years of age compared with patients younger than 70 years. Clin. Prostate Cancer 2(3), 167-172 (2003).
13. Sinibaldi VJ. Docetaxel treatment in the elderly patient with hormone refractory prostate cancer. Clin. Interv. Aging 2(4), 555-560 (2007).
14. Italiano A, Ortholan C, Oudard S et al. Docetaxel-based chemotherapy in elderly patients (age 75 and older) with castration-resistant prostate cancer. Eur. Urol. 55, 1368-1375 (2009).
15. Basch E, Autio K, Ryan CJ et al. Abiraterone acetate plus prednisone versus prednisone alone in chemotherapy-naive men with metastatic castration-resistant prostate cancer: patient-reported outcome results of a randomised Phase 3 trial. Lancet Oncol. 14, 1193-1199 (2013).
16. Beer TM, Armstrong AJ, Rathkopf DE et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N. Engl. J. Med. 371, 424-433 (2014).
17. Ryan CJ, Smith MR, Fizazi K et al. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled Phase 3 study. Lancet Oncol. 16, 152-160 (2015).
18. Heidenreich A, Bracarda S, Mason M et al. Safety of cabazitaxel in senior adults with metastatic castration-resistant prostate cancer: results of the European compassionate-use programme. Eur. J. Cancer 50, 1090-1099 (2014).
19. de Bono JS, Oudard S, Ozguroglu M et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 376, 1147-1154 (2010).
20. de Bono JS, Logothetis CJ, Molina A et al. Abiraterone and increased survival in metastatic prostate cancer. N. Engl. J. Med. 364, 1995-2005 (2011).
21. Scher HI, Fizazi K, Saad F et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N. Engl. J. Med. 367, 1187-1197 (2012).
22. Ryan CJ, Smith MR, de Bono JS et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N. Engl. J. Med. 368, 138-148 (2013).
23. Parker C, Nilsson S, Heinrich D et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N. Engl. J. Med. 369, 213-223 (2013).
24. Leibowitz-Amit R, Templeton AJ, Alibhai SM et al. Efficacy and toxicity of abiraterone and docetaxel in octogenarians with metastatic castration-resistant prostate cancer. J. Geriatr. Oncol. 6, 23-28 (2015).
25. Wong HL, Lok SW, Wong S, Parente P, Rosenthal M. Docetaxel in very elderly men with metastatic castration-resistant prostate cancer. Prostate Int. 3(2), 42-46 (2015).
26. Sartor AO, Oudard S, Ozguroglu M et al. Survival benefit from first docetaxel treatment for cabazitaxel plus prednisone compared with mitoxantrone plus prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC) enrolled in the TROPIC trial. J. Clin. Oncol. 29(Suppl.), Abstract 4525 (2011).
27. Chi KN, Scher HI, Molina A et al. Exploratory analysis of survival benefit and prior docetaxel (D) treatment in COU-AA-301, a Phase III study of abiraterone acetate (AA) plus prednisone (P) in metastatic castration-resistant prostate cancer (mCRPC). J. Clin. Oncol. 30(Suppl. 5), Abstract 15 (2012).
28. Sweeney CJ, Chen YH, Carducci M et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N. Engl. J. Med. 373(8), 737-746 (2015).
29. James ND, Sydes MR, Mason MD et al. Docetaxel and/or zoledronic acid for hormone-naïve prostate cancer: First overall survival results from STAMPEDE. J. Clin. Oncol. 33(Suppl.), Abstract 5001 (2015).